ASNC has confirmed reports that supply disruptions with both Tc-99m pyrophosphate (PYP) and Tc-99m hydroxymethylene diphosphonate (HMDP or HDP) may take place after January 2026. These products are used in the diagnosis of cardiac amyloidosis.
ASNC is in contact with the manufacturers of both products to understand the extent of the shortages and the projected timelines for resuming production.
ASNC will share updates as this issue evolves. To be among the first to receive email alerts with breaking news, be sure to keep your ASNC membership current.
Article Type
News & Announcements
Category
Advocacy
Related Posts
Medicare Telehealth Flexibilities Expire as Federal Government Partially Shuts Down
Congress’s failure to pass the remaining 6 fiscal year 2026 spending bills,…
Congressional Hearings on Healthcare Affordability: Insurance Execs Grilled on Prior Auth
Last week, the Energy and Commerce (E&C) Health Subcommittee and the Ways…
Cardiac PET, If Available, Is Now the Preferred Test for Evaluating CAD in All Patients
“Based on the clinical and scientific evidence now available, there are no…


